These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 14991160)

  • 21. Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease.
    Meurice T; Tricot O; Lemesle G; Deneve M; Lejeune P; Biausque F; Cordier C; Savoye C; Hennebert O; Taghipour K; Sivery B; Pruvost P; Alaoui M; Carpentier L; Segrestin B; Lamblin N; Bauters C
    Arch Cardiovasc Dis; 2015; 108(6-7):340-6. PubMed ID: 25858539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cardiovascular protection and prevention in patients with cardiac conditions and diabetes].
    Charpentier G; Puel J; Steg PG
    Presse Med; 2005 Oct; 34(18):1295-8. PubMed ID: 16269992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular disorders. Primary prevention.
    Murphy M; Foster C; Sudlow C; Nicholas J; Mulrow C; Ness A; Pignone M
    Clin Evid; 2002 Jun; (7):91-123. PubMed ID: 12230640
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Epidemiology and prevention of cardiovascular diseases].
    Jánosi A
    Orv Hetil; 2005 Apr; 146(15):683-8. PubMed ID: 15895792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The PreFord Study. A prospective cohort study to evaluate the risk of a cardiovascular event (overall-collective) as well as a prospective, randomized, controlled, multicentre clinical intervention study (high-risk-collective) on primary prevention of cardiovascular diseases in the Ford Motor Company employees in Germany].
    Gysan DB; Latsch J; Bjarnason-Wehrens B; Albus C; Falkowski G; Herold G; Mey E; Heinzler R; Montiel G; Schneider CA; Stützer H; Türk S; Weisbrod M; Predel HG
    Z Kardiol; 2004 Feb; 93(2):131-6. PubMed ID: 14963679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary and secondary prevention of cardiovascular disease in older adults: a status report.
    Kriekard P; Gharacholou SM; Peterson ED
    Clin Geriatr Med; 2009 Nov; 25(4):745-55, x. PubMed ID: 19944271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Secondary prevention after myocardial infarction].
    Pflumm JE; Pomykaj T; Heintzen MP
    Internist (Berl); 2008 Sep; 49(9):1052-60. PubMed ID: 18651118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Choosing the right medication for the right patient].
    Durand E; Kadri Z; Danchin N
    Rev Prat; 2005 Oct; 55(16):1805-11. PubMed ID: 16363431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lifestyle to prevent cardiovascular disease in NIDDM].
    Ezaki O
    Nihon Rinsho; 2006 Nov; 64(11):2083-8. PubMed ID: 17087300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"?
    Rastegarpanah M; Malekzadeh F; Thomas GN; Mohagheghi A; Cheng KK; Marshall T
    Arch Iran Med; 2008 May; 11(3):306-13. PubMed ID: 18426322
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect?
    Ishani A; Herzog CA; Collins AJ; Foley RN
    Kidney Int; 2004 Mar; 65(3):1017-25. PubMed ID: 14871422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary prevention of coronary artery disease in contemporary clinical practice.
    Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
    Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular prevention in type 2 diabetic patients: review of efficacious treatments.
    Goderis G; Boland B
    Acta Clin Belg; 2004; 59(6):329-39. PubMed ID: 15819377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prevention of cardiovascular disease in type 2 diabetes].
    Birkeland KI; Claudi T; Hansteen V; Hanssen KF; Hjermann I; Jenssen T; Jervell J; Os I
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2554-9. PubMed ID: 11070996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease.
    Sigvant B; Wiberg-Hedman K; Bergqvist D; Rolandsson O; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):39-46. PubMed ID: 19237996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Krakow Program for Secondary Prevention of Ischaemic Heart Disease. Part III. Secondary prevention of ischaemic heart disease after discharge].
    Kawecka-Jaszcz K; Jankowski P; Pajak A; Dubiel J; Maciejewicz J; Piotrowski W; Smielak-Korombel W; Tracz W
    Przegl Lek; 2001; 58(11):964-8. PubMed ID: 11987836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral arterial disease (PAD): secondary prevention.
    Völler H
    Dtsch Med Wochenschr; 2002 Sep; 127(37):1870-2. PubMed ID: 12226785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Arterial hypertension and the kidney].
    Niang A
    Dakar Med; 2008; 53(1):1-6. PubMed ID: 19102111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.